Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Zacks.com reports. The brokerage presently has a $4.50 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.66% from the stock’s current price.
According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
Other equities analysts have also recently issued research reports about the company. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Gabelli cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. They noted that the move was a valuation call. Wedbush reissued a “buy” rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Sunday, December 22nd. G.Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, BidaskClub cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 25th. Seven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.50.
Shares of NASDAQ:LXRX opened at $4.03 on Friday. Lexicon Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $8.39. The business has a 50-day moving average of $4.20 and a two-hundred day moving average of $3.62. The stock has a market capitalization of $428.28 million, a P/E ratio of -3.54 and a beta of 1.02. The company has a debt-to-equity ratio of 1.42, a current ratio of 8.11 and a quick ratio of 8.01.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The company had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. The business’s quarterly revenue was up 4124.5% compared to the same quarter last year. As a group, research analysts expect that Lexicon Pharmaceuticals will post 1.01 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC lifted its position in shares of Lexicon Pharmaceuticals by 40.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 4,746 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Lexicon Pharmaceuticals by 77.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock worth $388,000 after purchasing an additional 26,900 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Lexicon Pharmaceuticals during the third quarter valued at about $202,000. Swiss National Bank increased its stake in Lexicon Pharmaceuticals by 18.3% during the second quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock valued at $557,000 after acquiring an additional 13,700 shares during the period. Finally, AXA increased its stake in Lexicon Pharmaceuticals by 127.2% during the second quarter. AXA now owns 128,600 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 72,000 shares during the period. 96.24% of the stock is owned by institutional investors and hedge funds.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.